Anatara Lifesciences Limited

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

 
    

News

Anatara Lifesciences Ltd (ASX:ANR) Exclusive Global License Agreement with Zoetis

🕔5/15/2018 9:50:29 AM 7529

Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/19/2018 8:27:06 AM 7817

Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report

🕔2/22/2018 9:13:31 AM 7323

Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Achieves a Major US FDA Milestone in the Registration of Detach(R) with Approval of the Human Food Safety Dossier

🕔2/5/2018 8:29:16 AM 7568

Anatara Lifesciences (ASX:ANR) has achieved a significant milestone in the United States of America after receiving a "complete" letter from the US Food and Drug Administration for the Technical Section of its Human Food Safety submission. The HFS is a major component of a New Animal Drug Application which is currently underway and is necessary for enabling the marketing of Detach(R) in the US.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Receives $1.23m R&D Tax Refund

🕔1/18/2018 9:38:13 AM 7308

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Presents at Australasian Pig Science Association Conference

🕔11/21/2017 3:38:26 PM 5966

At the Australasian Pig Science Association Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide in reducing diarrhoea and antibiotic treatments in post-weaning piglets.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/13/2017 11:44:04 AM 6003

Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series

🕔11/3/2017 12:11:11 PM 6735

Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/18/2017 8:24:01 AM 5997

Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Annual Report 2017 Update

🕔10/4/2017 1:02:46 PM 5795

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.

Read Full Article▸
###

116,070 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 272) (Last 30 Days: 853) (Since Published: 116070) 

Company Data

    Headquarters
  • Level 3, 62 Lygon Street
    Carlton South, VIC, 3053
    Australia
    • Principal Sector
  • Biotech 
    • Principal Industry
  • Biotechnology 
    • Homepage
  • www.anataralifesciences.com
    • E:
  • info@anataralifesciences.com

Company Reports

More News Results

  • 2025/05/19: Hong Kong Patent Granted for GaRP*
  • 2025/05/16: Phase II GaRP-IBS Trial Internal Analyses of Data Subsets*
  • 2025/05/01: Funding Advance on R&D Refund*
  • 2025/04/30: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2025/04/17: Phase II GaRP-IBS Trial Headline Analysis of Results*
  • 2025/03/10: Phase II GaRP-IBS Trial & Anti-Obesity Project Updates*
  • 2025/03/07: Final Director's Interest Notice*
  • 2025/03/07: Initial Director's Interest Notice*
  • 2025/03/06: Trading Halt*
  • 2025/02/28: Board Changes*
*refer to company website

Latest Videos

Presentations

Download Presentation

Research Report

Download Presentation

Quarterly Report

Download Presentation

Annual Report

Download Annual Report

Social Media